CALCIUM CHANNEL BLOCKERS

1. PURPOSE

To authorize the CCP to monitor and adjust existing Calcium Channel Blocker (CCB) infusions

2. POLICY

2.1. CCP’s are permitted to monitor and adjust Calcium Channel Blocker infusions.
2.2. CCP’s may not initiate Calcium Channel Block infusions.

3. PRECAUTIONS

3.1. Use caution with patients with liver and renal disease.
3.2. Side effects can include dizziness, palpitations, fatigue, headache, and nausea.

4. PROCEDURE

4.1. Calcium channel blockers are used for a variety of reasons to include lowering blood pressure,
relaxation of blood vessels, slow and/or regulate heart rate, relieve angina, and for CAD.

4.2. CCB’s prevent calcium from entering the cells of the heart and arteries. Calcium causes the heart and
arteries to contract more strongly. By blocking calcium, CCB’s allow blood vessels to relax and open.
Some CCB’s are also used to slow down and regulate the heart rate.

4.3. Regulation of the infusion rate will occur within the parameters as defined by the transferring physician

or base hospital orders.

5. ADMINISTRATION

5.1. Common Calcium Channel Blockers and doses include, but not limited to, the following:

• Cardizem: 5 -15 mg/hr
• Nicardipine: 5 mg/hr and titrate q 10 mins by increments of 2.5 mg/hr for desired MAP
• Nifedipine: 10 mg PO q 20 mins and may repeat up to a max of 30 mg
• Clevidipine: 1-2 mg/hr with a max of 16 mg/hr

5.2. These medications and doses are for reference only. Transferring physician will select the medication

and dose for infusions with orders for transport guidelines and titration, if applicable.

12

